Nektar Therapeutics Cash Flow Conversion Efficiency
Nektar Therapeutics cash flow conversion efficiency. Based on the latest financial reports, Nektar Therapeutics (NKTR) has a cash flow conversion efficiency ratio of -0.084x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-75.77 Million) by net assets ($903.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Nektar Therapeutics (1994–2025)
Cash flow conversion efficiency of Nektar Therapeutics from 1994 to 2025. This chart illustrates how Nektar Therapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Nektar Therapeutics stock price today for real-time trading data and today's change.
Nektar Therapeutics Cash Flow Conversion Ratio Explained
Nektar Therapeutics cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Nektar Therapeutics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nektar Therapeutics ranked by their cash flow conversion efficiency. Also see Nektar Therapeutics stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Suzhou Jinhong Gas Co Ltd
SHG:688106
|
0.033x |
|
Amprius Technologies Inc.
NYSE:AMPX
|
-0.023x |
|
Ethos Technologies Inc. Class A Common Stock
NASDAQ:LIFE
|
0.075x |
|
Betsson AB
ST:BETS-B
|
0.074x |
|
HIAG Immobilien Holding AG
SW:HIAG
|
0.015x |
|
Cofco Biochemical Anhui Co Ltd
SHE:000930
|
0.039x |
|
ATAI LIFE SCIENCES BV EO1
F:9VC
|
N/A |
|
HBIS Resources Co Ltd
SHE:000923
|
0.010x |
Annual Cash Flow Conversion Efficiency for Nektar Therapeutics (1994–2025)
The table below shows the annual cash flow conversion efficiency of Nektar Therapeutics from 1994 to 2025. Review NKTR cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $89.83 Million | $-208.51 Million | -2.321x | +19.77% |
| 2024-12-31 | $60.74 Million | $-175.71 Million | -2.893x | -96.74% |
| 2023-12-31 | $130.99 Million | $-192.61 Million | -1.470x | -77.34% |
| 2022-12-31 | $366.64 Million | $-304.01 Million | -0.829x | -36.54% |
| 2021-12-31 | $679.51 Million | $-412.66 Million | -0.607x | -108.83% |
| 2020-12-31 | $1.08 Billion | $-313.29 Million | -0.291x | -24.35% |
| 2019-12-31 | $1.41 Billion | $-328.68 Million | -0.234x | -155.93% |
| 2018-12-31 | $1.72 Billion | $718.21 Million | 0.418x | +145.67% |
| 2017-12-31 | $87.83 Million | $-80.41 Million | -0.916x | +31.05% |
| 2016-12-31 | $88.12 Million | $-117.02 Million | -1.328x | +88.32% |
| 2015-12-31 | $6.43 Million | $-73.08 Million | -11.368x | -190.84% |
| 2014-12-31 | $36.33 Million | $-142.01 Million | -3.909x | -1012.07% |
| 2013-12-31 | $-89.90 Million | $-38.53 Million | 0.429x | +115.53% |
| 2012-12-31 | $47.02 Million | $-129.76 Million | -2.760x | -379.95% |
| 2011-12-31 | $197.81 Million | $-113.74 Million | -0.575x | +6.69% |
| 2010-12-31 | $90.66 Million | $-55.87 Million | -0.616x | -258.75% |
| 2009-12-31 | $102.37 Million | $39.74 Million | 0.388x | +150.64% |
| 2008-12-31 | $190.15 Million | $-145.78 Million | -0.767x | -212.37% |
| 2007-12-31 | $214.44 Million | $146.30 Million | 0.682x | +267.08% |
| 2006-12-31 | $227.06 Million | $-92.72 Million | -0.408x | -71.09% |
| 2005-12-31 | $326.81 Million | $-78.00 Million | -0.239x | -42.74% |
| 2004-12-31 | $467.34 Million | $-78.14 Million | -0.167x | +63.97% |
| 2003-12-31 | $164.19 Million | $-76.20 Million | -0.464x | -27.99% |
| 2002-12-31 | $206.77 Million | $-74.97 Million | -0.363x | -93.04% |
| 2001-12-31 | $270.31 Million | $-50.77 Million | -0.188x | -46.04% |
| 2000-12-31 | $277.88 Million | $-35.74 Million | -0.129x | +27.34% |
| 1999-12-31 | $86.63 Million | $-15.33 Million | -0.177x | -6.70% |
| 1998-12-31 | $115.88 Million | $-19.22 Million | -0.166x | -423.49% |
| 1997-12-31 | $97.09 Million | $4.98 Million | 0.051x | +131.03% |
| 1996-12-31 | $35.10 Million | $-5.80 Million | -0.165x | +37.02% |
| 1995-12-31 | $20.20 Million | $-5.30 Million | -0.262x | -1.01% |
| 1994-12-31 | $15.40 Million | $-4.00 Million | -0.260x | -- |
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosi… Read more